Last reviewed · How we verify

NCT06835452

Comparison of Current Subgingival Debridement Methods

Completed Last updated 19 February 2025
What this trial tests

trial in Treatment of Periodontitis in 90 participants. Completed in 7 February 2025.

Timeline
24 July 2024
Primary endpoint
1 February 2025
7 February 2025

Quick facts

Lead sponsorHacettepe University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment90
Start date24 July 2024
Primary completion1 February 2025
Estimated completion7 February 2025
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Hacettepe University

Who can join

Adults 18 to 45, female only, with Treatment of Periodontitis or Guided Biofilm Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our study aimed to compare the effectiveness of current subgingival debridement methods used in the treatment of Stage 1 and Stage 2 periodontitis patients, the aesthetic condition achieved after these treatments, and the pain felt during treatment. 90 female patients who were diagnosed with chronic periodontitis (Stage 1-2) and required supra-subgingival scaling for treatment purposes, and who volunteered to participate in the study, were included in the study. Three treatment groups were determined. 30 people were included in each group. Periodontal examination was performed before and after the treatments in the 1st month, 3rd month and 6th month and the data on the collected periodontal parameters were analyzed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Hacettepe University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06835452.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing